Equity · Healthcare
CSTL
NASDAQCastle Biosciences (CSTL)
The line runs 33.47 USD on 14 September through 33 USD on 14 October, on a scale from 32 to 38. Days the market did not trade hold the previous close, flat.
- Market cap
- 1.0B USD
- Revenue, year to Dec 2025
- 344.2M USD
- EPS, diluted, year to Dec 2025
- −0.83 USD
- 52-week range
- 18 USD – 43 USD
- Avg volume
- 49.9K
as of Oct 14, 2026
Have Castle Biosciences (CSTL) insiders bought or sold shares recently?
In the 90 days to 22 Nov 2026, Castle Biosciences insiders reported 22 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 14 Jul 2026, show no open-market purchase.
Form 4, 90 days to 22 Nov 2026, newest reported trade 16 Nov 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 16 Nov 2026 | MAETZOLD DEREK JPres. & Chief Exec. Officer | Sell | 6,942 | 229K USD |
| 11 Nov 2026 | Juvenal Tobin WChief Commercial Officer | Sell | 6,023 | 211K USD |
| 09 Nov 2026 | Juvenal Tobin WChief Commercial Officer | Sell | 3,288 | 107K USD |
| 02 Nov 2026 | MAETZOLD DEREK JPres. & Chief Exec. Officer | Sell | 14,496 | 523K USD |
| 28 Oct 2026 | Juvenal Tobin WChief Commercial Officer | Sell | 6,578 | 240K USD |
| 26 Oct 2026 | Juvenal Tobin WChief Commercial Officer | Sell | 3,288 | 109K USD |
| 19 Oct 2026 | MAETZOLD DEREK JPres. & Chief Exec. Officer | Sell | 14,496 | 463K USD |
| 12 Oct 2026 | Juvenal Tobin WChief Commercial Officer | Sell | 3,288 | 111K USD |
| 05 Oct 2026 | MAETZOLD DEREK JPres. & Chief Exec. Officer | Sell | 14,496 | 516K USD |
| 01 Oct 2026 | Oelschlager Kristen MChief Operating Officer | Sell | 4,153 | 149K USD |
| 30 Sep 2026 | Juvenal Tobin WChief Commercial Officer | Sell | 1,034 | 35K USD |
| 29 Sep 2026 | Juvenal Tobin WChief Commercial Officer | Sell | 5,543 | 197K USD |
| Sold | 22 open-market sales | 177,333 | $6.06M |
Showing the 12 most recent of 22 open-market trades in this window. The figures above count all of them.
8 other filings in the window: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 17 Nov 2026 | BRADBURY DANIELDirector | Gift | 5,985 | |
| 11 Nov 2026 | Juvenal Tobin WChief Commercial Officer | Option exercise | 3,195 | 94K USD |
| 05 Oct 2026 | MAETZOLD DEREK JPres. & Chief Exec. Officer | Option exercise | 8,165 | 20K USD |
| 01 Oct 2026 | Oelschlager Kristen MChief Operating Officer | Option exercise | 4,153 | 14K USD |
| 21 Sep 2026 | MAETZOLD DEREK JPres. & Chief Exec. Officer | Option exercise | 8,580 | 21K USD |
| 11 Sep 2026 | MAETZOLD DEREK JPres. & Chief Exec. Officer | Option exercise | 8,584 | 21K USD |
| 01 Sep 2026 | Oelschlager Kristen MChief Operating Officer | Option exercise | 4,152 | 14K USD |
| 28 Aug 2026 | MAETZOLD DEREK JPres. & Chief Exec. Officer | Option exercise | 12,428 | 30K USD |
Which funds hold Castle Biosciences (CSTL)?
8 of the 45 institutional funds we track reported a Castle Biosciences position for the quarter ended 30 Sep 2026 — a combined 69.1M USD; the latest of those filings landed 16 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Millennium Management | Added | 495,633 | 17.6M USD | +141.3% |
| AQR Capital Management | Added | 371,786 | 13.2M USD | +123.2% |
| Renaissance Technologies | Held (±25%) | 322,400 | 11.5M USD | −13.1% |
| Citadel Advisors | Held (±25%) | 300,799 | 10.7M USD | +13.4% |
| Two Sigma Investments | Added | 215,058 | 7.6M USD | +114.3% |
| Man Group | Held (±25%) | 99,365 | 3.5M USD | −8.6% |
| D. E. Shaw & Co. | Held (±25%) | 87,506 | 3.1M USD | −22.4% |
| Tudor Investment Corp | Added | 53,035 | 1.9M USD | +266.7% |
| Point72 Asset Management | Exited |
Have members of Congress traded Castle Biosciences (CSTL)?
The most recent congressional trade disclosed in Castle Biosciences is a sale by Josh Gottheimer (house, NJ), dated 15 Mar 2022.
STOCK Act disclosures
| Traded | Member | Type | Amount | Filed after |
|---|---|---|---|---|
| 15 Mar 2022 | Josh Gottheimerhouse · Democrat–NJ | Sale | 1K USD–15K USD | 33 days |
| 21 Dec 2020 | Josh Gottheimerhouse · Democrat–NJ | Purchase | 1K USD–15K USD | 17 days |
What has been filed or recorded for Castle Biosciences (CSTL)?
The filings we hold for Castle Biosciences, newest first: 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 30 Sep 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS −0.13 USD | Revenue $103M |
| 30 Sep 2026 | Financials | Total assets | 579.4M USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 478.4M USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −0.07 USD | Revenue $104M |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −0.49 USD | Revenue $84M |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −0.83 USD | Revenue $344M |
| 31 Dec 2025 | Financials | Revenue | 344.2M USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | −24.2M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −0.83 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −0.02 USD | Revenue $83M |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS 0.15 USD | Revenue $86M |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −0.90 USD | Revenue $88M |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS 0.62 USD | Revenue $332M |
What do people ask about Castle Biosciences (CSTL)?
What did Castle Biosciences shares close at?33.00
Castle Biosciences closed at 33.00 USD on 14 Oct 2026, up 0.36% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Castle Biosciences’ market cap?1.0B
Castle Biosciences is worth 1.0B USD by market value as of 14 Oct 2026, which is the share price times the shares on issue from its SEC filings.
What is Castle Biosciences’ revenue?344.2M
Castle Biosciences reported revenue of 344.2M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Castle Biosciences insiders bought or sold shares recently?22 sales
In the 90 days to 22 Nov 2026, Castle Biosciences insiders reported 22 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 14 Jul 2026, show no open-market purchase. A further 8 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders
Which funds own Castle Biosciences?8 of 45
8 of the 45 funds we track reported a Castle Biosciences position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were Millennium Management, AQR Capital Management and Renaissance Technologies. See Funds
Have members of Congress traded Castle Biosciences?2 trades
Yes. 2 trades in Castle Biosciences appear in the congressional disclosures we hold; the latest is a sale by Josh Gottheimer (House, NJ) dated 15 Mar 2022, filed 17 Apr 2022. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress
When did Castle Biosciences last report earnings?−0.13
Castle Biosciences last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.13 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- Wikimedia CommonsPortraits via Wikimedia Commons. Josh Gottheimer: Kristie Boyd; U.S. House Office of Photography, Public domain.
- House disclosuresU.S. House of Representatives financial disclosures
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings
- SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words